|
" Drug Delivery in Cancer Treatment II : "
edited by Lennart Domellöf.
| Document Type
|
:
|
BL
|
| Record Number
|
:
|
721053
|
| Doc. No
|
:
|
b540757
|
| Main Entry
|
:
|
edited by Lennart Domellöf.
|
| Title & Author
|
:
|
Drug Delivery in Cancer Treatment II : : Symptom Control, Cytokines, Chemotherapy\ edited by Lennart Domellöf.
|
| Publication Statement
|
:
|
Berlin, Heidelberg: Springer Berlin Heidelberg, 1989
|
| Series Statement
|
:
|
ESO Monographs, European School of Oncology.
|
| Page. NO
|
:
|
(vii, 107 pages 31 illustrations)
|
| ISBN
|
:
|
3642747094
|
|
|
:
|
: 9783642747090
|
| Contents
|
:
|
Analgesic Drugs in Palliative Care --;Pharmacokinetic Aspects of Drug-Drug and Drug-Plastic Interactions with Anticancer Drugs --;Immunotherapy and Interactions of Cytokines in the Host --;The Rationale of Intraarterial Chemotherapy of Liver Cancer --;Chemoembolisation in Regional Chemotherapy --;Optimised Treatment Modalities for Hypoxic Tumour Cells --;Drug Delivery to Cancer Patients in Home Care: Experience with Intraarterial and Intravenous Chemotherapy.
|
| Abstract
|
:
|
The European School of Oncology came into existence to respond to a need for information, education and training in the field of the diagnosis and treatment of cancer. There are two main reasons why such an initiative was considered necessary. Firstly, the teaching of oncology requires a rigorously multidiscipli nary approach which is difficult for the Universities to put into practice since their system is mainly disciplinary orientated. Secondly, the rate of technological development that impinges on the diagnosis and treatment of cancer has been so rapid that it is not an easy task for medical faculties to adapt their curricula flexibly. With its residential courses for organ pathologies and the seminars on new techniques (laser, monoclonal antibodies, imaging techniques etc.) or on the principal therapeutic controversies (conservative or mutilating surgery, primary or adjuvant chemotherapy, radiotherapy alone or integrated), it is the ambition of the European School of Oncology to fill a cultural and scientific gap and, thereby, create a bridge between the University and Industry and between these two and daily medical practice. One of the more recent initiatives of ESO has been the institution of permanent study groups, also called task forces, where a limited number of leading experts are invited to meet once a year with the aim of defining the state of the art and possibly reaching a consensus on future developments in specific fields of on cology.
|
| Subject
|
:
|
Internal medicine.
|
| Subject
|
:
|
Medicine.
|
| Subject
|
:
|
Toxicology.
|
| LC Classification
|
:
|
RC271.C5E358 1989
|
| Added Entry
|
:
|
Lennart Domellöf
|
| |